Effectively targeting deregulated KRAS signaling remains an unmet clinical need, as current approaches commonly lead to the development of chemoresistance in clinical settings. ADAM9-mediated lysosomal KRAS degradation is now shown to counteract PDAC chemoresistance independently of mutational status.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. CA Cancer J. Clin. 73, 17–48 (2023).
Waters, A. M. & Der, C. J. Cold Spring Harb. Perspect. Med. 8, a031435 (2018).
Punekar, S. R., Velcheti, V., Neel, B. G. & Wong, K.-K. Nat. Rev. Clin. Oncol. 19, 637–655 (2022).
Huang, Y.-K. et al. Nat. Cancer https://doi.org/10.1038/s43018-023-00720-x (2024).
Skoulidis, F. et al. New Engl. J. Med. 384, 2371–2381 (2021).
Jänne, P. A. et al. New Engl. J. Med. 387, 120–131 (2022).
Zhao, Y. et al. Nature 599, 679–683 (2021).
Awad, M. M. et al. New Engl. J. Med. 384, 2382–2393 (2021).
Bond, M. J., Chu, L., Nalawansha, D. A., Li, K. & Crews, C. M. ACS Cent. Sci. 6, 1367–1375 (2020).
Miyamoto-Sato, E. et al. Molecules 28, 5600 (2023).
Shin, W. et al. Exp. Mol. Med. 50, 1–10 (2018).
Yamamoto, K. et al. J. Gastroenterol. 57, 603–618 (2022).
Hosein, A. N., Dougan, S. K., Aguirre, A. J. & Maitra, A. Nat. Cancer 3, 272–286 (2022).
Rojas, L. A. et al. Nature 618, 144–150 (2023).
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G. & Galluzzi, L. Cancer Cell 39, 310–345 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.H. holds stocks in Encellin Inc. and Thymmune Therapeutics Inc., consults for CV Next and holds stocks in the company, and is the co-founder of Minutia Inc. and holds stocks and options in the company. L.L. declares no competing interests.
Rights and permissions
About this article
Cite this article
Leonhardt, L., Hebrok, M. KRAS degradation averts PDAC chemoresistance. Nat Cancer 5, 375–377 (2024). https://doi.org/10.1038/s43018-023-00708-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-023-00708-7